Immunocore Holdings plc (IMCR) Reports 70% Two-Year Survival in 17-Patient Cohort
Immunocore (IMCR) reported a 70% two-year survival rate in 17 patients treated with brenetafusp plus tebentafusp, with a median follow-up of 29 months. The company plans a randomized Phase 2/3 trial. The data is from an early-stage cohort, and the next catalyst is the planned trial.
How this was made
The 30-second read
Why it matters
The 70% two‑year survival suggests a strong efficacy signal, potentially increasing investor interest ahead of the planned Phase 2/3 DUET‑UVEAL trial.
Market read
First disclosure of promising trial data; may drive short‑term stock movement and longer‑term valuation considerations.
What to watch
Regulatory review timeline and competitive landscape for T‑cell therapies.
Background
Immunocore is a UK‑based biotech developing T‑cell redirecting therapies. The reported data comes from a first‑line patient cohort receiving brenetafusp plus tebentafusp.
Ticker impact
Immunocore reported 70% two‑year overall survival in a 17‑patient Phase 1/2 cohort, a first‑time disclosure of this clinical data.
potential upside as market prices in the strong survival signal
The data is novel and material for a biotech; however, the cohort is small and further trials are needed.
Market effects
May boost sentiment for early‑stage oncology immunotherapies.
Limited to UK/US biotech investors.
Minor, confined to biotech sector.
Counterpoint
Small sample size could lead to over‑optimism; caution on short‑term price moves.
Key entities
- companyImmunocore Holdings plc
Biotech developer of T‑cell therapies.